Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent

IL-31 Inhibitor On File In US And EU

 
• By Mandy Jackson

Galderma presented long-term extension data from its Phase III trials in atopic dermatitis and prurigo nodularis at AAD for its first-ever therapeutic biologic, taking on a formidable competitor.

Different light bulb glowing in a line
Galderma is set to position nemolizumab as a unique option • Source: Shutterstock

More from Clinical Trials

More from R&D